Skip to main content

Table 5 Evolution in memory outcomes according to combined plasma MCP-1 and Aβ42/40 status

From: Plasma MCP-1 and changes on cognitive function in community-dwelling older adults

Period Aβ42/40−a/MCP1−b
n = 195
Aβ42/40/MCP1+
n = 85
Aβ42/40+ /MCP1
n = 97
Aβ42/40+ /MCP1+
n = 52
Between-group difference (95% CI)c Between-group difference (95% CI)c Between-group difference (95% CI)c Between-group difference (95% CI)c
FCSRT free recall,n= 383
 12 months −1.10 (−1.47, −0.72) −0.61 (−1.75, 0.52) −3.26 (−4.87, −1.65) * −2.74 (−4.76, −0.73)**
 24 months −0.46 (−0.86, −0.06) −0.95 (−2.14, 0.25) −4.24 (−5.94, −2.54) *** −2.36 (−4.51, −0.21)*
 36 months −1.30 (−1.76, −0.84) −1.58 (−2.90, −0.27)* −4.46 (−7.64, −2.55) *** −1.81 (−4.17, 0.54)
 48 months −1.47 (−1.97, −0.98) −1.51 (−2.90, −0.11)* −4.22 (−7.71, −2.17) *** −3.31 (−5.89, −0.73)*
FCSRT total recall,n= 383
 12 months −0.60 (−0.84, −0.36) −0.95 (−1.61, −0.30) −2.24 (−3.17, −1.30)*** −1.88 (−3.06, −0.71)***
 24 months −0.18 (−0.45, 0.08) −0.71 (−1.43, 0.004) −2.29 (−3.31, −1.26)*** −1.92 (−3.22, −0.62)**
 36 months −0.92 (−1.24, −0.61) −0.63 (−1.45, 0.18) −2.32 (−3.53, −1.12)*** −2.08 (−3.56, −0.60)**
 48 months −0.81 (−1.17, −0.46) −0.45 (−1.35, 0.45) −3.14 (−4.48, −1.81)*** −2.54 (−4.22, −0.86)**
FCSRT free delayed recall,n= 383
 12 months −0.10 (−0.27, 0.06) −0.25 (−0.70, 0.21) −1.12 (−1.76, −0.48)*** −1.48 (−2.29, −0.68)**
 24 months −0.11 (−0.28, 0.07) −0.28 (−0.76, 0.20) −1.38 (−2.06, −0.70)*** −1.14 (−2.01, −0.28)*
 36 months −0.24 (−0.44, −0.04) −0.61 (−1.14, −0.07)* −1.37 (−2.15, −0.59)*** −0.86 (−1.82, 0.08)
 48 months −0.38 (−0.60, −0.17) −0.69 (−1.26, −0.13)* −1.90 (−2.74, −1.06)*** −1.28 (−2.33, −0.23)*
FCSRT total delayed recall,n= 383
 12 months −0.07 (−0.15, 0.01) −0.22 ( −0.43, −0.01)* −0.57 (−0.87, −0.26)*** −0.66 (−1.04, −0.28)***
 24 months −0.06 (−0.15, 0.03) −0.32 (−0.57, −0.08)** −0.72 (−1.07, −0.37)*** −0.51 (−0.95, −0.07)*
 36 months −0.25 (−0.36, −0.14) −0.20 (−0.49, −0.08) −1.00 (−1.43, −0.58)*** −0.46 (−0.98, 0.07)
 48 months −0.26 (−0.39 , −0.13) −0.45 (−0.78, −0.13)** −1.20 (−1.69, −0.72)*** −0.93 (−1.54, −0.31)**
  1. *p value < 0.05; **p value < 0.001; ***p value < 0.001: significant differences in the evolution of the outcomes (Aβ42/40-/MCP1 as reference group)
  2. #p value < 0.05; ##p value < 0.001;###p value < 0.001: significant difference in the evolution of the outcomes between Aβ42/40+ /MCP1 and Aβ42/40+ /MCP1+ groups
  3. Models were adjusted by sex, age, BMI, MAPT group, CDR status at baseline, GDS score, and ApoE ε4 genotype
  4. Abbreviations: Aβ42/40 β-amyloid 42aa isoform/β-amyloid 40aa isoform ratio, FCSRT Free and Cued Selective Reminding Test, MCP-1 Monocyte Chemoattractant Protein-1
  5. aAbnormal Aβ42/40 defined as values ≥ 107 pg/mL
  6. bAbnormal MCP-1 defined as values in the 4th quartile (> 251 pg/mL)
  7. cNegative values indicate worsening performance along follow-up